JPWO2020113188A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020113188A5
JPWO2020113188A5 JP2021531217A JP2021531217A JPWO2020113188A5 JP WO2020113188 A5 JPWO2020113188 A5 JP WO2020113188A5 JP 2021531217 A JP2021531217 A JP 2021531217A JP 2021531217 A JP2021531217 A JP 2021531217A JP WO2020113188 A5 JPWO2020113188 A5 JP WO2020113188A5
Authority
JP
Japan
Prior art keywords
subject
cells
composition
administration
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021531217A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513689A5 (https=
JP2022513689A (ja
JP7652692B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/063883 external-priority patent/WO2020113188A2/en
Publication of JP2022513689A publication Critical patent/JP2022513689A/ja
Publication of JP2022513689A5 publication Critical patent/JP2022513689A5/ja
Publication of JPWO2020113188A5 publication Critical patent/JPWO2020113188A5/ja
Application granted granted Critical
Publication of JP7652692B2 publication Critical patent/JP7652692B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021531217A 2018-11-30 2019-11-29 養子細胞療法におけるb細胞悪性腫瘍の投与および処置のための方法 Active JP7652692B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862774168P 2018-11-30 2018-11-30
US62/774,168 2018-11-30
US201862774858P 2018-12-03 2018-12-03
US62/774,858 2018-12-03
US201962847897P 2019-05-14 2019-05-14
US62/847,897 2019-05-14
US201962854957P 2019-05-30 2019-05-30
US62/854,957 2019-05-30
US201962931143P 2019-11-05 2019-11-05
US62/931,143 2019-11-05
PCT/US2019/063883 WO2020113188A2 (en) 2018-11-30 2019-11-29 Methods for dosing and treatment of b cell malignancies in adoptive cell therapy

Publications (4)

Publication Number Publication Date
JP2022513689A JP2022513689A (ja) 2022-02-09
JP2022513689A5 JP2022513689A5 (https=) 2022-12-06
JPWO2020113188A5 true JPWO2020113188A5 (https=) 2022-12-06
JP7652692B2 JP7652692B2 (ja) 2025-03-27

Family

ID=68982440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531217A Active JP7652692B2 (ja) 2018-11-30 2019-11-29 養子細胞療法におけるb細胞悪性腫瘍の投与および処置のための方法

Country Status (17)

Country Link
US (1) US20220031746A1 (https=)
EP (2) EP3886894B1 (https=)
JP (1) JP7652692B2 (https=)
KR (1) KR20210110811A (https=)
CN (1) CN113692285A (https=)
AU (1) AU2019387494A1 (https=)
BR (1) BR112021010120A2 (https=)
CA (1) CA3120363A1 (https=)
DK (1) DK3886894T3 (https=)
ES (1) ES2986007T3 (https=)
FI (1) FI3886894T3 (https=)
IL (2) IL283298B2 (https=)
MX (1) MX2021006244A (https=)
PL (1) PL3886894T3 (https=)
PT (1) PT3886894T (https=)
SG (1) SG11202105380RA (https=)
WO (1) WO2020113188A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3234120B1 (en) 2014-12-15 2025-09-03 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
EP4400516A1 (en) 2014-12-15 2024-07-17 The Regents of the University of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
DK3368571T5 (da) 2015-10-30 2024-09-30 Univ California Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf
MA46995A (fr) 2016-12-03 2019-10-09 Acerta Pharma Bv Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
EP3704230B1 (en) 2017-11-01 2024-10-23 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
CN112262214A (zh) 2018-04-12 2021-01-22 优莫佳生物制药股份有限公司 病毒载体及包装细胞系
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
EP4271817A2 (en) 2020-12-30 2023-11-08 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2117571C3 (de) 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (https=) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
FR2688138B1 (fr) 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
CA2147466A1 (en) 1992-10-20 1994-04-28 Just P. J. Brakenhoff Interleukin-6 receptor antagonists
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
ATE186235T1 (de) 1996-04-24 1999-11-15 Claude Fell Zelltrennungsvorrichtung für biologische flüssigkeiten wie blut
WO1999018129A1 (en) 1997-10-02 1999-04-15 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
JP2002524081A (ja) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 前立腺−特異的膜抗原に特異的な融合受容体およびその使用
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
HK1041454B (en) 1998-12-24 2004-12-31 生物安全股份有限公司 Blood separation system particularly for concentrating hematopoietic stem cells
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
AU2002321581C1 (en) 2001-08-31 2008-09-18 Adaptimmune Limited Soluble T cell receptor
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
CA2824167C (en) 2002-09-06 2018-09-25 Amgen Inc. Therapeutic human anti-il-1r1 monoclonal antibody
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
CA2570817A1 (en) 2004-06-17 2006-01-26 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
US8361794B2 (en) 2004-06-29 2013-01-29 Immunocore Limited Cells expressing a modified T cell receptor
US7645755B2 (en) 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
MX2007011218A (es) 2005-03-23 2007-10-17 Biosafe Sa Sistema integrado para colectar, procesar y transplantar subconjuntos de celulas, incluyendo celulas madre adultas para medicina regenerativa.
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
EP2680006A1 (en) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Treatment for Amyotrophic Lateral Sclerosis
CA2682527C (en) 2007-03-30 2017-07-11 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
WO2009072003A2 (en) 2007-12-07 2009-06-11 Miltenyi Biotec Gmbh Sample processing system and methods
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
RS56844B1 (sr) 2007-12-11 2018-04-30 Univ North Carolina Chapel Hill Retrovirusni vektori sa modifikovanim polipurinskim nizom
AU2009209251B8 (en) 2008-01-28 2015-03-26 Medimmune Limited Stabilized Angiopoietin-2 antibodies and uses thereof
WO2009099553A2 (en) 2008-02-01 2009-08-13 The Regents Of The University Of California Use of kinase inhibitor in treatment of atherosclerosis
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
EP4032552B1 (en) 2008-08-26 2023-10-04 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
US20100190755A1 (en) 2008-09-19 2010-07-29 Paul Abato Tetracycline compounds for the treatment of rheumatoid arthritis and related methods of treatment
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
DK2496698T3 (en) 2009-11-03 2019-04-15 Hope City TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN110200997A (zh) 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
HUE032754T2 (en) 2011-05-05 2017-10-30 Novartis Ag CSF-1R inhibitors for the treatment of brain tumors
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
KR102134932B1 (ko) 2011-11-11 2020-07-17 프레드 헛친슨 켄서 리서치 센터 암을 위한 사이클린 a1―표적화된 t―세포 면역요법
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
US20150119267A1 (en) 2012-04-16 2015-04-30 Sloan-Kettering Institute For Cancer Research Inhibition of colony stimulating factor-1 receptor signaling for the treatment of brain cancer
SG10201609210SA (en) 2012-05-03 2016-12-29 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
JO3754B1 (ar) 2012-06-04 2021-01-31 Pharmacyclics Llc أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
CA2881981A1 (en) 2012-08-20 2014-02-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
AU2013327136A1 (en) 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
DE112012007250B4 (de) 2012-12-20 2024-10-24 Mitsubishi Electric Corp. Fahrzeuginterne Vorrichtung und Programm
EP2970905B1 (en) 2013-03-15 2019-10-16 Stemcell Technologies Inc. Compositions and methods for obtaining enriched mesenchymal stem cell cultures
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
AU2014268364A1 (en) 2013-05-24 2015-12-10 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
CN113354744A (zh) 2013-12-20 2021-09-07 弗雷德哈钦森癌症研究中心 带标签的嵌合效应分子及其受体
CA2945320A1 (en) * 2014-04-10 2015-10-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Drug regulated transgene expression
RU2763795C2 (ru) 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
DK3166968T3 (da) 2014-05-02 2021-12-06 Univ Pennsylvania Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
CN107109438B (zh) 2014-11-05 2021-09-03 朱诺治疗学股份有限公司 用于转导及细胞处理的方法
MA45341A (fr) * 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
EP3704230B1 (en) 2017-11-01 2024-10-23 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells

Similar Documents

Publication Publication Date Title
US20230115328A1 (en) Anti-B7-H1 and Anti-CTLA-4 Antibodies for Treating Non-Small Cell Lung Cancer
US20250163152A1 (en) Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
Carvalho et al. Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti‐cancer antibodies: IUPHAR Review 18
US20180319892A1 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
JP2021501606A5 (https=)
JP2019532997A5 (https=)
EP3621694B1 (en) Lrrc33 inhibitors and use thereof
TW201625270A (zh) 用於治療贅瘤形成的治療組合及方法
TW201642897A (zh) Her2結合劑治療
CN116322769A (zh) 用于治疗多发性骨髓瘤的方法
Shui et al. Bispecific antibodies: unleashing a new era in oncology treatment
JP7809635B2 (ja) Lag-3アンタゴニスト治療のための定量的空間プロファイリング
JPWO2020113194A5 (https=)
JPWO2020113188A5 (https=)
CN119095619A (zh) 抗cd19药剂的剂量方案及其用途
US20220154296A1 (en) Use of anti-pd-1 antibody in preparation of medicament for treating solid tumors
CN119156228A (zh) 抗tigit抗体及其用途
US20250215087A1 (en) Combination therapy of kras inhibitor and treg depleting agent
KR20240038769A (ko) 항-ilt3 항체를 사용하여 급성 골수성 백혈병을 치료하는 방법
WO2025226541A2 (en) Klk2xcd3 antibody and an anti-cancer agent for treating prostate cancer
JP2023554422A (ja) がんの治療のための多重特異性抗体
EP4136105A1 (en) Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein
KR20220058601A (ko) 확장 병기 소세포 폐암(es-sclc)을 치료하기 위한 조성물 및 방법
US20260042835A1 (en) Methods for treating chronic myelomonocytic leukemia with anti-ilt3 antibodies
CA3212604A1 (en) Methods for treating cancer with anti-ilt3 antibodies